Overview

Epanova® for Lowering Very High Triglycerides

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AstraZeneca